AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2 and is expected to complete cohort 3 in January; 6-month and 12-month amyloid PET data expected in H1 & H2 2024, respectivelyReTain Phase 2b clinical trial of ACI-35.030 in preclinical AD being launched now by partner VacSYn Phase 2 PD trial of ACI-7104.056 completed enrollment of cohort 1 and commenced cohort 2; safety and immunogenicity update expected in H2 2024Cash for operations extends into 2026 with USD50 million equity financing and ACI-35.030-related milestones Lausanne, Switzerland, January 3, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today provided an update on positive progress in its active immunotherapy programs, with three Phase 2 trials progressing to key clinical milestones in 2024.

AC免疫进展阿尔茨海默病和帕金森病2期主动免疫治疗临床管道的更新ACI-24.060的ABATE 1b/2期AD试验完成了队列1和2的登记，预计将于1月完成队列3；2024年上半年和下半年预计将有6个月和12个月的淀粉样蛋白PET数据，ACI-35.030在临床前AD中的2b期临床试验正在由ACI-7104.056的合作伙伴VacSYn 2期PD试验启动。完成队列1的登记并开始队列2；2024年下半年预计的安全性和免疫原性更新通过5000万美元的股权融资和ACI-35.030相关里程碑瑞士洛桑，2024年1月3日-AC Immune SA（纳斯达克股票代码：ACIU），一家临床阶段的生物制药公司，开创了神经退行性疾病的精准医学，今天提供了其主动免疫治疗计划积极进展的最新情况，其中三项2期试验在2024年取得了关键的临床里程碑。

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune has continued steady clinical development progress throughout 2023, and we end the year in a very strong position. We now have three active immunotherapies from our precision medicine pipeline in Phase 2 clinical testing, with key milestones for ACI-24.060 in 2024.

AC Immune SA首席执行官Andrea Pfeifer博士评论道：“AC Immune在整个2023年持续稳步的临床开发进展，我们在年底处于非常有利的地位。我们现在从精准医学管道中获得了三种积极的免疫疗法，用于第二阶段临床测试，2024年ACI-24.060的关键里程碑。

We are moving ever closer to delivering therapeutics that use the immune system to slow the onset and ultimately prevent neurodegenerative diseases, much like vaccines for infectious disease. To succeed, we must pursue earlier diagnoses and begin using active immunotherapies before permanent damage occurs to neurons.” “Our financial position was reinforced in December by our successful USD50 million equity offering, which was supported by some of the world’s preem.

我们越来越接近于提供利用免疫系统减缓发病并最终预防神经退行性疾病的治疗方法，就像传染病疫苗一样。为了取得成功，我们必须进行早期诊断，并在神经元发生永久性损伤之前开始使用主动免疫疗法。”“12月，我们成功进行了5000万美元的股票发行，并得到了一些全球优先股的支持，从而巩固了我们的财务状况。

Attachment

附件

20240103_ACIU_PipelineUpdate_FINAL

20240103_ACIU_PipelineUpdate_FINAL